As the CFO said they'll essentially slash SGA expenses moving forward. It seems they are trying to live thru the next 2 years of declining rev by reducing exp with a big CF payday in 2015 and beyond. If those drugs work then they will generate rev of at least 3-4b.
Another option is to reduce their dev exp by shutting down or selling off programs. I don't think vrtx is big enough to bring a flu drug or a RA drug to market. Both molecules look good so far but they could sell or partner with both to progress them further. Would reduce expenses a lot. Most people working these clinical programs would not be needed and would be laid off. I think the latter is a better option.